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The main source of data for the studies presented in this thesis has been the 
computerised database of the New Somerset and Groote Schuur Hospital HIV 
outpatient clinics. This extremely valuable source exists of meticulously collected 
data of more than ten thousand outpatient visits over a thirteen year period by 
-physicians dedicated to the care of HIV positive patients. Without access to this 
database, these studies could not have been performed. 
Dr. Robin Wood, head of the Somerset Hospital HIV clinic, has initially stimulated 
my interest in HIV infection, and subsequently supervised most of the research 
conducted over the years. As supervisor of this thesis, he has provided invaluable 
support and guidance for the studies, and comprehension of the various computer 
programs required to analyze the data. 
Prof. Gary Maartens, head of the HIV clinic at Groote Schuur Hospital, has been an 
excellent tutor of the clinical aspects of HIV infection. He has provided the original 
concept for the study presented in chapter 3, and important assistance and 
discussion for the studies in chapter 3 and 5. 
The staff of the Somerset Hospital HIV clinic, and specifically Sister Liz Fielder, for 
encouragement and the ability to find mislaid folders. 
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In sub-Saharan Africa, resource-limitation results in scarce availability of HIV 
prognostic tools such as CD4+ T-Lymphocyte (CD4) count and HIV viral load. To 
facilitate counselling and cli!'1ical decisions in this setting, widely available and 
inexpensive markers of prognosis are required. 
Chapter one gives an overview of the epidemiology and pathophysiology of HIV 
infection (with particular reference to sub-Saharan Africa), and its clinical 
manifestations. Staging systems for HIV infection and aspects of management in 
resource-poor environments are briefly discussed. 
Chapter two describes the epidemiological , pathophysiological and cl inical 
aspects of tuberculosis (TB) in HIV infected patients, the commonest 
opportunistic infection in sub-Saharan Africa. It further provides HIV and TB 
prevalence data from the Western Cape, South Africa. 
In chapter three a study is pre~ented demonstrating the usefulness of the total 
lymphocyte count (TLC) in combination with the World Health Organisation 
(WHO) cl inical staging system to predict outcome in 831 HIV positive patients. 
A TLC of 1250/µL was found to be the equivalent of a CD4 count of 200/µL. 
Patients with early HIV disease (WHO stage 1 & 2) had low annual rates of 
progression to AIDS : 3-4% if the TLC was above 1250/µL, 12-14% if the TLC 
was below 1250/µL. Annual progression to AIDS increased to 25% and 46% in 
patients with clinical stage 3 and a TLC above or below 1250/µL respectively. 
Patients with AIDS had 30-55% one-year mortality rates depending on the TLC. 
Chapter four illustrates that pulmonary tuberculosis (PTB) in HIV infected 
patients presents with a radiographic spectrum reflecting the degree of HIV 
induced immune suppression. Chest radiographs and pre-treatment total 
lymphocyte counts provide prognostic information. 
Upper zone cavitatory infiltrates typical of reactivation PTB were associated with 
a preserved CD4 count (mean 389/µL) and predicted a 100% two-year survival. 
Pleural effusions were associated with a mean CD4 count of 184/µL and 
predicted 65% two-year survival. Patients with atypical radiographic 
presentation, including lower and mid-zone infiltrates, hilar and mediastinal 
adenopathy or interstitial patterns, had low CD4 counts (mean 105/µL) and a 
36% survival at two years. 
Rather than classifying every patient with pleura-pulmonary tuberculosis as 
WHO stage 3, incorporation of the prognostic value of the chest radiograph into 
the clinical staging system, such that typical reactivation PTB becomes stage 2, 
tuberculous pleural effusion stage 3 and atypical PTB stage 4, would enhance 
the prognostic accuracy of HIV related tuberculosis. 
Chapter five demonstrates that patients with AIDS could be categorized 
according to one of three survival patterns, relating to the type of opportunistic 
illness. One-year survival rates were highest for extra-pulmonary tuberculosis 
V 
and herpes simplex virus infection (70% ); intermediate for oesophageal 
candidiasis, cryptococcal meningitis, kaposi sarcoma and pneumocystis carinii 
pneumonia (45%); and poorest for the HIV wasting syndrome, AIDS-dementia 
complex and performance status 4 (20%). Despite the overall poor prognosis 
associated with the acquired immunodeficiency syndrome, a substantial 
proportion of patients survive, even in the absence of anti-retroviral therapy, for a 
number of years. 
Chapter six concludes by proposing how the data presented in this thesis could 
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1 a INTRODUCTION 
In 1981, an outbreak of Pneumocystis carinii pneumonia (PCP) and Kaposi 





previously healthy men were noted to have very low numbers of circulating 
helper-T-lymphocytes 3. The CD4+T-lymphopenia rendered these patients 
susceptible to a wide spectrum of infections and malignancies. 
In 1983, a virus to be classified among the lentivirus family of retroviruses, was 





virus subsequently was renamed human immunodeficiency virus (HIV) type 1, 
and the clinically manifested susceptibility to opportunistic infections labelled 
acquired immunodeficiency syndrome (AIDS). It appeared that following 
seroconversion, HIV infection was characterized by a prolonged period of 
clinical latency prior to the onset of opportunistic infections and AIDS. 
Although the initial epidemic was recognized in homosexual men in the United 
States, the majority of patients in resource-poor countries acquired HIV infection 
via heterosexual transmission. The number of HIV infected patients worldwide 
was estimated to have reached 30.6 million by late 1997, the majority of cases 
(approximately 20.8m) were living in sub-Saharan Africa 
6
. Most African 
countries have reported a rise in HIV seroprevalence throughout the 1990's, and 
the projected cumulative figure for Africa is 40 million by 2000. HIV infection was 
also rapidly spreading through Asia, whereas the HIV epidemic appeared to 
have stabilized in the developed world 7. 
A second human T-cell lymphotropic virus associated with the acquired 
immunodeficiency syndrome was first described in west Africa, and is now 
2 
known as HIV-2 8. Human immunodeficiency virus type 2 infection is rare outside 
the West-African region, and compared to HIV-1 less transmissible, associated 
with a lower rate of progression to AIDS and a lower mortality 
9
. Over 10 
subtypes of HIV-1 infection have been described since its discovery, and are 
categorized according to the degree of difference in their env coding region as 
major (M; up to 30% variance) or outlier (0, approximately 50% structural 
homology) 10. The majority of HIV-1 infected individuals in sub-Saharan Africa 
carry subtype A, whereas in South Africa the dominant subtypes are C in 
heterosexually transmitted cases and subtype B in homosexually acquired 
infections 11 . The clinical implications of infection with particular subtypes of HIV, 
particularly the sensitivity of diagnostic tests, long-term response to anti-
retroviral therapy and specificity of protection afforded by future vaccines 
remains unclear 10. 
By 1990, the HIV prevalence in the general population of many African countries 
had reached 1-10%. Higher seroprevalence rates were reported in selected 
individuals such as young, sexually active persons and hospitalized patients (up 
to 30%) or sexually transmitted diseases (STD) clinic attendees, truck drivers 
and prostitutes (up to 60%). HIV incidence rates ranged from approximately 1 % 
in the general population to more than 20% in the highest risk groups 
12
. 
Consequently, health services in many African countries became overwhelmed 
with HIV positive patients, and HIV/AIDS a major cause of death in hospitalized 
patients. HIV infection also became an important cause of loss of productive 
work force, and by depriving elderly of their support system and causing children 




The principle mode of HIV transmission in sub-Saharan Africa is heterosexual 
intercourse. In this light, the high prevalence of STD's in Africans may have 
contributed to the rapid transmission of HIV throughout Africa 
14
. In the absence 
of a cure for HIV infection, interventions aimed at the reduction of HIV 
transmission have been emphasized. These include the counselling of 
individuals at risk of acquiring HIV infection regarding HIV/AIDS, high risk sexual 
behaviour and the use of condoms, and the treatment of STD's 
15
. Although 
successful in having increased the awareness of AIDS, these measures have 
not been able to prevent the spread of HIV infection amongst millions of 
Africans. Other interventions, such as the reduction of vertical transmission by 
administration of anti-retroviral therapy to pregnant women, have remained too 
expensive for most African countries. A significant reduction in HIV related 
morbidity and mortality in sub-Saharan Africa may only be realizable once an 
effective and affordable HIV vaccine becomes available. 
1b PATHOGENESIS OF HIV INFECTION AND AIDS 
Human immunodeficiency virus infection results in the majority of patients in a 
progressive depletion of mononuclear cells expressing the CD4 surface 
molecule. The loss of these important components of the immune system results 
in an increased susceptibility to a variety of micro-organisms. 
After entering the host, human immunodeficiency virus infects cells that express 
CD4 molecules on their membrane (lymphocytes, monocytes, macrophages and 
dendritic cells). The CD4 molecule acts as receptor for HIV envelope 
glycoprotein, and attachment of HIV to CD4 and the chemokine receptors 
4 
CXCR4 (fusin) and CCRS leads to introduction of viral RNA into the host cell 
16
. 
The viral enzyme reverse transcriptase creates a DNA template, which becomes 
incorporated into host DNA. HIV DNA may remain latently present in the host 
genome, or be transcribed by host DNA polymerase, resulting in the production 
of viral genomic RNA and viral precursor proteins. Several enzymes, cleaved 
from the precursor proteins by viral protease, are required for the assemblance 
of the HIV virion within the host cell. Production of HIV virions may result in 
death of the host cell. The HIV virions, once released, will rapidly invade 
uninfected CD4 expressing mononuclear cells, thereby commencing a new cycle 
of HIV replication 17'18. 
The production of billions of HIV virions each day results in a massive turnover 
of CD4+T-lymphocytes. Initially, the loss of CD4+T-cells is matched by a 
markedly increased rate of production. With time and for reasons unclear, a 
progressive decline in number and function of CD4 cells occurs 
19
. This is 
reflected clinically by the increased susceptibility to infections caused by 
organisms normally contained or rapidly cleared by mononuclear cells. 
Currently available anti-retroviral therapy is aimed at decreased HIV replication. 
Nucleoside analogues, such as zidovudine (AZT), didanosine (ddl), zalcitabine 
(ddC), lamivudine (3TC) and stavudine (d4T), and non-nucleoside reverse 
transcriptase inhibitors (NNRTI) such as nevirapine and decaviridine inhibit the 
viral protein reverse transcriptase and thus interfere with the production of a 
DNA template prior to insertion into host genome. Protease inhibitors such as 
indinavir and ritonavir interfere with virion assembly. Anti-retroviral agents have 
been shown to reduce HIV viral load and improve CD4 counts, particularly when 
5 
given in combination. Clinically, this is reflected by a reduction in number of 





1c CLINICAL MANIFESTATIONS OF HIV INFECTION 
Acute HIV infection may, in 50-70% of patients, present as an infectious 
mononucleosis-like illness with fever, malaise, lymphadenopathy and rash, or in 
others remain asymptomatic. The "seroconversion illness" may be associated 
with significant immunosuppression, and opportunistic infections typical of AIDS 
may temporarily occur. A milder seroconversion illness is predictive of a 
subsequent more benign course of HIV infection 
20
. 
A period of clinical latency follows seroconversion, during which generalized 
lymphadenopathy may be the only clinical clue to underlying HIV infection 
21
. 
During asymptomatic HIV infection, an extremely high turnover of CD4+T-cells is 
associated with a gradual reduction in the number of circulating T-lymphocytes. 
This period may last many years or even decades, and the HIV viral load, in 
combination with CD4 count, is commonly used to monitor progression of HIV 
induced immune suppression and predict long term outcome 
18
. 
The first symptoms of HIV infection may relate to relatively minor illnesses, such 
as skin rashes, upper respiratory tract infection, or mild unintentional weight 
loss. Alternatively, patients can present with more serious complications such as 
prolonged fever or diarrhoea, weight loss more than 10%, thrush, severe 
bacterial infections or AIDS-defining illnesses. Symptomatic HIV infection is 
preceded by an increased rate of CD4+T-lymphocyte depletion 18. 
6 
Once severe immune suppression is present (CD4 counts commonly below 
200/µL), AIDS-defining opportunistic infections may occur with increased 
frequency. A variety of pathogens (including non-tuberculous mycobacteria, 
fungi , protozoa and viruses) that are an uncommon cause of disease in 
immunocompetent individuals, may lead to life threatening illnesses in patients 
with AIDS. Following successful treatment of these opportunistic infections, most 
patients will require lifelong chemoprophylaxis to prevent a clinical relapse. With 
progressive deterioration of cellular immunity, multiple opportunistic infections 
may occur simultaneously and eventually result in death of the HIV infected 
patient 18. The reduced immune surveillance also predisposes patients with 
advanced HIV infection to malignancies, including non-Hodgkin lymphoma, anal 
and cervical sqamous cell carcinoma 
22
. Kaposi sarcoma is not a true 
malignancy, and may be related to concurrent human herpes virus-8 (HHV-8) 
infection, which is particularly prevalent in homosexually acquired HIV infected 
patients 22 . 
Prior to combination anti-retroviral therapy, median survival of patients with AIDS 
was generally poor and averaged 10.4 months 
23
. However, the use of HIV 
suppressive therapy in conjunction with multiple primary and secondary 
prophylaxis regimen appears to have improved the outcome for those who are 
able to afford these drugs. 
The commonest presentation of AIDS in Africa is weight loss, asthenia, and 
fever. Diarrhoea, cough and skin rash are frequently reported. In comparison to 
AIDS in the developed world, pulmonary and extra-pulmonary tuberculosis, 
cryptococcal meningitis, toxoplasmosis and cryptosporidiosis appear to occur 
7 
with increased frequency in Africa, whereas pneumocystis carinii pneumonia 
(PCP) and non-tuberculous mycobacterial infections are less frequently reported 
24
. The true prevalence of PCP in Africans remains controversial as 
sophisticated techniques are usually required to confidently make this diagnosis. 
Studies from Zimbabwe using fibre-optic bronchoscopy documented the 





contrast, PCP was found in the alveolar lavage fluid of only 1 of 127 HIV positive 
patients with lung disease in Tanzania 
27
. At Somerset Hospital, Cape Town, the 
shift in patient characteristics from homosexual white males to heterosexual 
African males and females over a 12 year period was accompanied by a 
significant reduction of PCP as AIDS defining diagnosis from 41 to 12% 
28
. 
A post mortem study from West Africa revealed that tuberculosis was the 
commonest (54%) disease present in patients dying with AIDS, followed by 
cytomegalovirus (26%), pyogenic pneumonia and cerebral toxoplasmosis (21 %), 
Kaposi sarcoma ( 13%) and non-specific enteritis ( 12% ), whereas the prevalence 
of PCP, cryptococcosis and cryptosporidiosis was 4-5% 
29
. An important finding 
was that tuberculosis contributed significantly to the wasting syndrome. The 
majority of deaths were due to infections, including tuberculosis, bacteraemia, 
toxoplasmosis and pyogenic pneumonia, and thus potentially treatable or 




1d STAGING OF HIV INFECTION AND MARKERS OF DISEASE 
PROGRESSION 
Based on clinical and laboratory parameters, several classification systems for 
HIV infection have been proposed 30-32 (see addendum at the end of this 
chapter). The most useful system in the African context appears to be the World 
Health Organization proposed clinical staging system 30. In this classification, 
HIV positive patients can be entered into one of four stages according to 
performance status and clinical illnesses. By allowing the use of presumptive 
diagnoses, total lymphocyte counts, and performance status, the WHO system 
has easy applicability in resource-poor settings. Each stage reflects the degree 
of immune compromise and carries prognostic value 33. The Walter Reed system 
31 requires CD4 counts and assessment of delayed hypersensitivity, and does 
not specify the type of opportunistic infection. The Centres for Diseases Control 
(CDC) system 32 classifies the type of opportunistic disease but makes no 
distinction between early and late events. The CDC classification was modified 
in 1993 to include patients with CD4 counts <200/µI, pulmonary tuberculosis, 
recurrent bacterial pneumonia and invasive cervical cancer in group C (AIDS 
defining conditions 34. 
The CD4+T-lymphocyte count is the most frequently used, and probably most 
useful of markers to monitor progression of HIV infection 35. HIV viral load has 
also been shown to predict long term outcome in HIV infection. Access to CD4 
counts or HIV viral load however is extremely limited in Africa. These markers 
are therefore of limited use to clinicians for management of HIV infected 
patients. 
9 
In resource-poor settings, the combination of WHO clinical stage and total 
lymphocyte count can be used to predict progression to AIDS (see chapter 3). In 
HIV positive patients with tuberculosis, the chest radiograph has important 
prognostic value (see chapter 4). The type of AIDS-defining illness and 
performance status are important determinants of survival in patients with AIDS 
(see chapter 5). 
1e MANAGEMENT OF HIV INFECTION IN AFRICA 
The rate of progression from asymptomatic to symptomatic HIV infection in 
Uganda was similar to reported figures from the developed world 36. Survival of 
patients with AIDS attending the same HIV clinic in Cape Town, South Africa, 
compared for the 2 transmission patterns (which reflected race, education and 
socio-economic status), showed that African patients had similar survival to 
patients of European descent 37. This supports the suggestion that access to 
medical care may be an important determinant of survival of African patients with 
HIV infection. As in the developed world, treating patients with HIV infection in 
Africa may be rewarding, both in human and economical terms, and HIV positive 
patients should therefore be provided with the same standard of care as HIV 
negative patients. 
The majority of the millions of Africans latently infected with HIV will eventually 
develop symptomatic disease. The burden placed by HIV infection and AIDS on 
the existing medical facilities of sub-Saharan countries is already overwhelming, 
and can be expected to increase. Resources for treating HIV positive patients 
10 
will have to be rationed so as not to disproportionally impede the health care for 
HIV negative patients. 
HIV positive patients would be best cared for in specialized AIDS clinics, as the 
outcome of HIV infected patients is improved when they receive care from 
doctors who have experience with HIV infection 38. Patients could be monitored 
for the presence of treatable intercurrent illnesses, and receive ongoing 
counselling. Early outpatient intervention may avoid a costly hospital admission 
subsequently. The formulation of national guidelines for the investigation, 
(empirical) treatment, and referral of patients with symptomatic HIV infection that 
take the restraints on the country's health care resources into consideration, 
may facilitate management decisions and promote a more equal distribution of 
care. Home-based care, particularly for patients in the pre-terminal phase of 
their disease, will become increasingly important as the demand for hospital 
beds rises. Traditional medicine has a limited role to play in a curative strategy 
for the complications of HIV infection, but remains an important source of 
palliative care for terminally ill patients 39. 
Relatively inexpensive intervention aimed at the reduction of HIV transmission 
by altering high risk sexual behaviour, treatment of concurrent sexually 
transmitted diseases, and the administration of specific anti-retroviral therapy 
such as zidovudine to pregnant women should be considered. Low cost 
preventive therapy is available for tuberculosis and bacterial infections. The 
logistics, both in infrastructural and financial terms, associated with isoniazid 
prophylaxis to prevent active TB may preclude its widespread implementation in 
11 
Africa. Co-trimoxazole prophylaxis however should be considered for 
significantly immunocompromised patients. 
12 
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S1AG[ HTlV Ill CHQOHIC T HCLPUI OHS THIWS11 0 .1 . 
Ali1UODY lYMPHAOEH· C [ LLS/mml 
AJ-40/0R V\RVS CPA.THY 
IS0l.Atl0N 
woo > -4 00 NL 
w, , 0 > -4 00 NL 
WR2 © 0 ::- -4 00 NL 
WOl 0 ® NL 
W1! .- 0 ®@ 
W1! s 0 • ' < -400 
w•• 0 < 400 PC © 
Figure 1. The Walter Recd Staging Classification fo r HTLV-flf / 
LAV Infection. 
The essential criteria for assignment 10 each stage are indicated 
by hatched hexagons. OHS denotes delayed hypersensitivity; NL, 
normal; P, partial cutaneous anergy, which is defined as an intact 
cula·neous response lo only one of lhe four lest antigens (see 
lexl); C. complete cutaneous ancrgy lo the four lest antigens; 
and 0 .1.. opportunistic infection. 
Walter-Reed classification system for HL TV-Ill/LAV infection (ref 31) 
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ADDENDUM (continued) 
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2a TUBERCULOSIS AND HIV IN SUB-SAHARAN AFRICA 
Some 1700 million people worldwide, or one third of the human population, are 
infected with Mycobacterium tuberculosis (MTS). Annually, 8m people develop 
active tuberculosis (TB), resulting in 2.9m deaths. Africa, home to 12% of the 
world population, carried 64% of the global TB burden, 65% of the global human 
immunodeficiency virus (HIV) burden and almost 80% of the estimated 4M cases 
of HIV/TB co-infection in 1992. The interaction between human 
immunodeficiency virus and Mycobacterium tuberculosis has lead to a marked 
increase in the number of tuberculosis cases in sub-Saharan Africa 1. 
HIV infection is an important risk factor for developing active tuberculosis. 
Studies comparing incidence rates of tuberculosis in HIV negative and HIV 
positive Africans indicate that HIV infection is associated with a 6-23 fold relative 
risk for developing active TB, as TB annual incidence rates ranged 0.2-0.8% in 
HIV negative and 5-8% in HIV positive persons. Based on these figures, it was 
estimated that in 1992 alone, HIV infection was responsible for an additional 
150.000-250.000 cases of tuberculosis in Africa. Tuberculosis became by far the 
commonest opportunistic illness in HIV infected patients in Africa 1. 
Approximately half of all Africans have acquired MTS infection by adolescence. 
As HIV infection became more prevalent in this population, many countries in 
sub-Saharan Africa reported an increase in tuberculosis case loads. Notification 
rates more than doubled over a five year period in Burundi , Malawi and Zambia. 
HIV prevalence in African patients with pulmonary TB was noted to be as high 
as 70%. The HIV related surge in TB case load has posed a major burden on the 
already stretched TB services of many sub-Saharan African countries 1. 
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Anti-tuberculous chemoprophylaxis given to HIV infected individuals may reduce 
the high tuberculosis incidence rate observed in these persons. An initial report 
from Haiti suggested that six months isoniazid reduced the number of clinical TB 
cases and possibly improved survival 2. A larger Ugandan study showed that 
various prophylaxis regimen were able to offer protection against tuberculosis in 
PPD-positive HIV infected adults, however no survival benefit could be 
demonstrated 3. A large Kenyan study in individuals with early and advanced 
HIV infection failed to show a significant beneficial effect of six months isoniazid 
preventive therapy, regardless whether patients were PPD-positive or negative 4. 
To date, TB chemoprophylaxis has not been widely implemented in sub-Saharan 
Africa, because of expense of widespread HIV testing, the reluctance of persons 
undergoing HIV testing to be confronted with the result of the test, insufficiency 
of the existing TB infrastructure to supervise prophylaxis, anticipated high 
default rates that may lead to a rise in drug resistance, drug toxicity, the difficulty 
of confidently ruling out active tuberculosis prior to commencing prophylaxis, 
uncertainty about the duration of protection and the possible lack of efficacy in 
advanced HIV infection 5·6·7. 
As HIV infection becomes more prevalent in sub-Saharan Africa, the number of 
TB cases is likely to rise even further. The increased patient load will 
necessitate more patients to receive ambulatory TB treatment. Highly efficacious 
rifampicin based short-course anti-tuberculous chemotherapy is the treatment of 
choice, as shorter duration of therapy may improve patient compliance and 
increased cure rates facilitate TB control. Ambulatory patients should receive 
this treatment under direct observation (DOTS), as drug resistance may be the 
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result of intermittent compliance to therapy. Supervision is facilitated by the use 
of a twice weekly administered modified rifampicin-based treatment regimen, 
and has been shown to achieve excellent cure rates 8. In an attempt to limit 
costs, the use of non-professional people to supervise ambulatory TB treatment 
has been encouraged, and shown to be very successful in a rural South African 
community 9. 
2b PATHOPHYSIOLOGY OF HIV RELATED TUBERCULOSIS 
In immunocompetent individuals, following aerosol infection and phagocytosis by 
pulmonary macrophages, Mycobacterium tuberculosis will elicit both a cell-
mediated immune and a delayed hypersensitivity reaction in lung tissue and 
regional lymph nodes. CD4+ T-lymphocytes are important regulators of the 
induced immune response. 
Cell-mediated immunity involves an incompletely understood interplay between 
Th1 CD4+ T-cells that produce interferon-y and interleukin (IL)-2, cytokine-
activated macrophages that produce tumour necrosis factor-a, IL-1 and IL-6, and 
cytotoxic CD4+ yo T-cells. Cell mediated immunity leads to granuloma formation 
at the site of infection, and macrophage activation results in killing of 
phagocytosed mycobacteria. Delayed hypersensitivity, an important mechanism 
for clearing mycobacteria that escape killing by cell-mediated immunity, acts by 
macrophage lysis. This may result in the release of macrophage proteinases, 
nucleases and lipases into host tissue, which by causing local inflammation may 
lead to caseation and cavity formation 10·11 . Most persons with a competent 
immune system will thus contain MTB infection. A number of organisms may 
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remain dormant within macrophages, from which TB may reactivate, even 
decades later. 
In HIV infection, most patients with time develop, in relation to dysfunction and 
depletion of CD4+ T-cells, progressive impairment of both cell-mediated 
immunity and delayed hypersensitivity. This results in an increased rate of 
reactivation of latent tuberculosis, and an increased susceptibility to (re)infection 
with MTB. In early HIV infection, preserved immunity shows a reactive 
histological pattern and pauci-bacillary TB, similar to that in HIV negative 
patients. The immune response is sufficiently preserved for cavitation to occur, 
and sputum smears are typically positive at this stage. As HIV disease 
advances, granulomas show gradual depletion of CD4+ T-cells and diminished 
caseation. Tuberculosis in severely immune compromised patients is 
characterized pathologically by multi-bacillary TB and absent granuloma 
formation 11, and clinically by frequent dissemination to extra-pulmonary sites 12. 
The absence of cavity formation in advanced HIV infection underlies the 
frequent smear negativity. 
2c CLINICAL ASPECTS OF HIV RELATED TUBERCULOSIS 
Similar to TB in HIV negative patients, the lung is the commonest site of 
tuberculosis in HIV infection. Pulmonary TB may occur at all stages of HIV 
infection 13. The clinical and radiographic presentation of pulmonary TB, 
including the diagnostic yield of smears, shifts from typical smear positive TB in 
early HIV infection to atypical, frequently smear negative TB with advanced 
immune compromise. 
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In early HIV infection, TB occurs in the setting of a relatively preserved immune 
response, and resembles TB in HIV negative individuals. Tuberculosis at this 
stage is predominantly pulmonary, and dissemination to extra-pulmonary sites 
occurs infrequently. The clinical and radiographic features are those of TB in 
HIV negative patients, with cavitating upper zone infiltrates on chest radiograph. 
Sputum smears are typically positive, and clinical signs of underlying immune 
compromise such as oral candidosis or kaposi sarcoma are usually absent. 
Generalized lymphadenopathy may be a clue to underlying HIV infection 14-17. 
As HIV-induced immune suppression becomes more pronounced, the 
presentation of TB becomes increasingly more atypical, and concurrent extra-
pulmonary tuberculosis more frequent. Lymph nodes, pleura, pericardium and 
abdomen are the more common sites of extra-pulmonary TB, meningitis and 
osteitis occur less frequently. Clinical examination at this stage may reveal 
thrush, oral hairy leukoplakia, or evidence of previous herpes zoster. 
Radiographically, a shift towards atypical patterns (adenopathy, interstitial 
infiltrates, and pleural effusions) reminiscent of primary infection occurs 15-17. The 
sputum smear remains the most important diagnostic tool, but its yield may be 
reduced. Enlarged lymph nodes may reveal acid-fast bacilli and, if present on 
clinical examination, should be considered for diagnostic fine needle aspiration. 
Sputum culture is almost invariably positive and may confirm the diagnosis in 
retrospect. 
In patients with AIDS, tuberculosis not infrequently recurs and may contribute 
significantly to morbidity and mortality 18. At this stage, tuberculosis may be 
entirely or predominantly extra-pulmonary, and chest radiographs may be 
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normal, even in the presence of positive sputum smears and cultures 17. Patients 
frequently present with features of severe immune compromise, a wasting illness 
and pyrexia. The diagnosis may be extremely difficult to confirm; mycobacterial 
blood culture and histological examination of liver or bone marrow may be 
required. Clinical outcome is poor, even in patients with a microbiological 
response. 
Sputum culture has shown that tuberculosis in Africa is almost entirely due to 
M.tuberculosis infection, and that HIV infection is not associated with an 
increased rate of drug resistant TB 8'14'19. Optimum treatment of TB in HIV 
positive patients is directly observed, short-course chemotherapy (2 months 
isoniazid + rifampicin + pyrazinamide + ethambutol , followed by 4 months 
isoniazid + rifampicin). Rifampicin-based chemotherapy has been shown to be 
more efficacious and better tolerated than conventional TB therapy 20. Rifampicin 
allowed a reduction of treatment duration to 6 months without impairing cure 
rate, and was associated with very few treatment failures 8. Lower rates of 
treatment completion have been reported in HIV positive patients with 
tuberculosis, mainly due to HIV-related mortality 8•21 -23. Atypical radiographic 
presentation, oral candidosis and low CD4 count were predictors of mortality in 
HIV related PTB 24. 
2d HIV AND TB IN THE WESTERN CAPE, SOUTH AFRICA 
The countrywide HIV prevalence for South African adults, based on the sampling 
of women attending ante-natal clinics, was estimated at 14.17% (95%CI 13.45-
14.89) in 1996. This indicated a significant increase compared to 1995 (10.44%) 
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and 1994 (7.57%), and HIV prevalence was shown to be rising in all age groups. 
Within South Africa, large regional variation of HIV prevalence rates was 
observed, ranging from 3% in the Western Cape to more than 25% in the North 
West Province 25 . Data from the 1996 survey suggested that HIV infection is not 
equally distributed within the Western Cape population, as none of 35 Whites, 
0.3% (2/787) of Coloureds and 4.7% (17/361) of Blacks tested positive for HIV at 
the time that overall HIV prevalence was 1.7% 26. No HIV prevalence figures for 
males have been published to date. Caution is required when extrapolating HIV 
prevalence data obtained from antenatal surveys to the general population, as 
the reduced pregnancy rate of HIV positive women may result in underestimation 
of the magnitude of the HIV epidemic in this population 27. 
Tuberculosis incidence and prevalence rates for the Cape Town area are more 
difficult to obtain. Population statistics for many of the townships where TB is 
highly prevalent are rough estimates, and the Black population is highly mobile. 
In 1995, the estimated overall tuberculosis incidence rate was 372/100.000, 
ranging from less than 25/100.000 for Whites and Asians to approximately 400 
and 800/100.000 for Coloureds and Blacks respectively 28. In certain high-
density residential areas in Cape Town, incidence rates as high as 
1339/100.000 have been reported 29. 
Cape Town therefore is at the interface of two epidemics: tuberculosis 
prevalence and incidence rates are among the highest in the world, and HIV 
infection is rapidly spreading in this population. A surge of tuberculosis can be 
anticipated in the Black population as HIV infection becomes even more 
prevalent, and more HIV infected persons develop significant immune 
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compromise. Data from Somerset hospital (a local state hospital serving some of 
the communities with high HIV and TB prevalence rates) revealed a large 
increase in tuberculosis admissions between 1990 and 1995. This increase was 
entirely accounted for by HIV positive patients, whereas the number of HIV 
negative patients with TB remained unchanged 30. The overall HIV prevalence 
rate of patients admitted to Somerset hospital with TB and prior unknown HIV 
status was 39% in 1995-1996: 37% in Coloured and 53% in Black patients. 
Tuberculosis in these hospitalized patients had developed in the presence of 
advanced HIV-induced immune suppression (median CD4+ T-cell count 65/µL 
for both pulmonary or extra-pulmonary TB). Whereas drug-resistant TB was 
frequently encountered in the small number of White male homosexuals, HIV 
infection in the Black and Coloured patient population was not associated with 
an increased rate of (multi-) drug resistant tuberculosis 31 . 
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CHAPTER THREE 
WHO CLINICAL STAGE AND TOTAL LYMPHOCYTE COUNT PREDICT THE 
RATE OF PROGRESSION OF HIV INFECTION 
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CD4 AND TOTAL LYMPHOCYTE COUNT: EQUAL PREDICTORS OF HIV 
DISEASE PROGRESSION? 
SUMMARY 
CD4+T.;.lymphocyte (CD4) counts are a standard laboratory marker of disease 
progression in HIV infection, but expense precludes their use in large parts of 
the world. Total lymphocyte counts (TLC), in contrast, are widely available. We 
compared CD4 and TLC counts as predictor of developing AIDS or death in 831 
HIV positive outpatients (582 males and 249 females with both homosexual 
(males, n=316) and heterosexual (n=515) transmission patterns. The first CD4 
count <200/µL and first TLC <1250/µL predicted similar (p=0.52) survival , 
irrespective of clinical stage. For each clinical stage, a significant difference in 
progression to AIDS and mortality was predicted by a TLC above or below 
1250/µL (p<0.03). Survival and progression to AIDS occurred at similar rates in 
patients with a TLC <1250/µL or a CD4 count <200/µL (p>0.1 ), and patients with 
a TLC >1250/µL or a CD4 count >200/µL (p>0.5). A TLC <1250/µL preceded the 
development of Pneumocystis carinii pneumonia (PCP) or cerebral 
toxoplasmosis in 76% of patients. In this longitudinal study, TLC and CD4 counts 
were equal predictors of disease progression. A TLC below 1250/µL could be 
considered an indication for commencing cotrimoxazole prophylaxis. 
(Q J Med 1996; 89:505-508) 
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INTRODUCTION 
HIV infection can be monitored by laboratory 1•2 and clinical 3'4 markers of 
disease progression. The CD4+T-lymphocyte (CD4) count is considered the best 
laboratory marker of progression of HIV infection 1, but lacks uniform 
reproducibility 5, is a crude predictor of HIV disease progression when taken by 
itself 6, and, because of expense, has limited availability in both resource-poor 
and developed countries 7. 
In the absence of CD4+T-lymphocyte counts, the use of total lymphocyte counts 
(TLC) has been advocated to predict CD4 count 8 and to stage HIV disease 4•9. 
The use of the TLC as predictor of CD4+T-lymphocyte count is limited by the 
presence of CD4+T-lymphopenia in up to 30% of non-lymphopenic patients 8. 
However, a low TLC was found to predict progression to clinical AIDS 2·10. This 
longitudinal study compared total lymphocyte count with CD4 count as predictor 
of hard clinical end-points (developing AIDS and death) in lymphopenic and non-
lymphopenic HIV positive patients. 
METHODS 
Computer-based medical records of Somerset and Groote Schuur Hospital HIV 
clinics, two principal Western Cape HIV out-patient clinics, were analysed. 
Patients had been staged clinically (retrospectively from 1984 to 1991, 
prospectively from 1992 onwards) at each visit according to the WHO clinical 
staging system 9, in which stage 4 is equivalent to the 1987 Centres for Diseases 
Control (CDC) definition of AIDS 11 . Most patients that presented with serious 
HIV related complications were admitted to hospital in an attempt to confirm the 
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diagnosis pathologically or microbiologically. Depending on the clinical condition 
of the patient and/or response to empiric therapy, spinal fluid sampling, live'r and 
bone marrow biopsy, bronchosopy, CT scanning and occasionally brain biopsy 
was used to enhance diagnostic certainty. HIV encephalopathy was diagnosed 
in the appropriate clinical context and after the presence of concurrent 
opportunistic illnesses had been excluded, PCP and cerebral toxoplasmosis 
frequently remained a presumptive diagnosis. Paired CD4 and TLC values 
(n=1965) were available in 831 patients. CD4 counts were determined by flow 
cytometry and total lymphocyte counts by automated blood cell counter. 
Lymphopenia was defined as a TLC <1250/µL. 
Survival was expressed as the Kaplan-Meier estimate of cumulative probability 
of survival and was calculated in months from the index visit (first visit at which 
CD4 or TLC occurred in the defined range) to the date of death (not censored) 
or last visit (censored). Similarly, AIDS free survival was calculated from the 
index visit to the date of initial AIDS diagnosis/death (not censored) or last visit 
( censored). 
Survival curves were created for various degrees of lymphopenia (increments of 
250 lymphocytes) and compared for closest fit to the curves of a CD4 count 
below 200 and 50/µL. Optimal match of the survival curve of a CD4 count 
<200/µL was achieved by a TLC <1250/µL. Probability of AIDS-free and overall 
survival was therefore determined for each clinical stage and a TLC above or 
below 1250/µL or a CD4 count above or below 200/µL. Statgraphics version 6.0 
was used to create Kaplan-Meier plots and the log-rank test to establish 
statistical difference between survival curves. 
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RESULTS 
Patients of the two HIV clinics represented both homosexual (n=316) and 
heterosexual (n=515) transmission pattern, male (n=582) and female (n=249) 
sex, and the three local population groups (whites n=280, blacks n=339 and 
mixed-race n=212). Intravenous drug abuse and haemophilia did not occur as 
risk factors for HIV infection in our patients. Mean age was 31.9 years (range 12-
77), and increased with clinical stage (range 29.7-34.7 for stage 1 to 4, p<0.02). 
Mean age was higher for patients with CD4 counts below 200/µL (34.1 vs 30.4, 
p<0.01) and TLC below 1250/µL (33.2 vs 31 .3, p<0.01) compared to patients 
with preserved CD4 or total lymphocyte counts. 
A CD4 count <200/µL occurred in 81 % (547 of 675) of total lymphocyte counts 
<1250/µL and a CD4 count >200/µL was present in 80% (1032 of 1290) of TLC 
>1250/µL. A total lymphocyte count <1250/µL was 68% sensitive and 89% 
specific for a CD4 count <200/µL. A TLC >1250/µL or a CD4 count >200/µL 
predicted the absence of clinical AIDS in 90% and 94% of patients respectively. 
Survival of patients of any clinical stage whose total lymphocyte count had 
declined below 1250/µL was similar to the survival of patients with a first CD4 
count below 200/µL (Figure 1 ). Survival of patients (n=132) with a first TLC 
below 750/µL was not statistically different (p=0.37) from patients (n=146) who 
had a CD4 count below 50/µL (45% at one year and 20% at two years). In 
lymphopenic patients (TLC <1250/µL) as well as patients with a CD4 count 
<200/µL, clinical stage was a major determinant of mortality (Figure 2a,b ). 
Progression to AIDS and death occurred at significantly (p<0.03) higher rates in 
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lymphopenic patients than in non-lymphopenic (TLC >1250/µL) patients (Table 
1 ). Mortality and progression to AIDS were not significantly different (p>0.5) 
between patients of similar clinical stage and a TLC <1250/µL or a CD4 count 
<200/µL (Figure 2a-d) , nor between patients with a TLC >1250/µL and patients 
with a CD4 count >200/µL (p>0.1, data not shown). 
Pneumocystis carinii pneumonia (PCP) was diagnosed in 51 patients and 
cerebral toxoplasmosis in 8. In the 12 months preceding the onset of PCP or 
toxoplasmosis, a TLC <1250/µL was present in 76% of these patients. 
DISCUSSION 
The CD4+T-lymphocyte count is considered the best laboratory marker of 
progression of HIV infection 1, and serial CD4 count determinations are 
commonly performed to monitor the degree of HIV induced immunosuppression. 
Low CD4 counts are indicative of decreased cellular immunity and associated 
with increased risk of developing AIDS or death. In the absence of CD4 counts, 
the use of total lymphocyte counts has been advocated to predict CD4 count and 
to stage HIV disease 4'8 '9 . The usefulness of the total lymphocyte count is best 
evaluated by direct comparison with CD4 count as predictor of hard endpoints 
such as AIDS and death. This study found CD4 and TLC to be equal predictors 
of progression of HIV infection. The routine use of total lymphocyte counts rather 
than CD4 counts would substantially reduce the costs associated with managing 
HIV infection. 
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The WHO staging system incorporates the use of TLC <1000, 1000-2000 and 
>2000/µL to replace CD4 counts <200, 200-500 and >500/µL in its laboratory 
axis 9. In Rwandan HIV positive women, few of whom had severe lymphopenia, a 
TLC above or below 2000/µL had no prognostic value 12 . Our results suggest 
that a TLC of 1250 rather than 1000/µL should be the equivalent of a CD4 count 
of 200/µL, and the presence of a TLC above or below 1250/µL is associated with 
a significant difference in rates of progression of HIV infection. 
In two previous studies, patients of various WHO clinical and/or laboratory 
stages were rearranged into 4 "modified stages", and survival was determined 
for each "modified stage" 4'12. In our patients, TLC (and CD4 counts) added 
independent, prognostically meaningful information to the WHO clin ical stage 
(Table 1 ). The stratification of patients by WHO clinical stage and absence or 
presence of lymphopenia is easily performed and practical for the management 
of HIV infection in resource-poor countries. 
In advanced HIV infection, the total lymphocyte count declines as a result of 
progressive depletion of CD4+T-lymphocytes, CDB+T-lymphocytes and 8-
lymphocytes 13. CDB+T-lymphopenia was found to be an independent predictor 
of mortality 14, and the decrease in 8-cells may further contribute to the 
immunodeficient state associated with advanced HIV infection. In our patients, 
severe lymphopenia (TLC <750/µL) predicted poor survival regardless of clinical 
stage and might reflect a high susceptibility to opportunistic infections. In one 
study, systemic Mycobacterium avium complex infection was restricted to 
patients with severe lymphopenia (mean 540/µL) 15. 
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Cotrimoxazole is effective prophylaxis against toxoplasmosis, PCP and bacterial 
infections, and is recommended for all patients with CD4 counts <200/µL 16. 
Although PCP is less common in Africa, toxoplasmosis and bacterial infections 
are major causes of mortality 17. As lymphopenia preceded the development of 
PCP or toxoplasmosis in 76% of our patients, a TLC <1250/µL could be 
considered a criterion for instituting cotrimoxazole prophylaxis. 
A TLC >1250/µL was only 4% less sensitive than a CD4 count >200/µL as 
predictor of the absence of clinical AIDS. Using lymphopenia rather than CD4 T-
lymphopenia as a criterion for commencing cotrimoxazole prophylaxis may thus 
select a slightly smaller group of patients at risk for developing PCP. Although 
we have shown the total lymphocyte count to be equal to the CD4 count for 
overall prognosis, its usefulness in individual patients as a criterion for 
commencing prophylaxis needs to be studied prospectively. 
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TABLE 
One year Kaplan-Meier estimate of progression to clinical AIDS (WHO stage 1-
3) and death (WHO stage 4), stratified by a total lymphocyte count (TLC) above 
or below 1250/µL. 
One-year progression to AIDS 
Stage 1 
TLC > 1250/µL 3% 





Stage 2 Stage 3 
4% 25% 
12% 46% 
SURVIVAL (ALL STAGES) 
- CD4 <200 (n = 235) 
- - - TLC <1250 (n = 184) 








Figure 1. Overall survival for HIV-positive patients from the first CD4 count 
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CHAPTER FOUR 
CHEST RADIOGRAPHS REFLECT IMMUNE STATUS IN HIV INFECTED 
PATIENTS WITH PULMONARY TUBERCULOSIS 
4a PULMONARY TUBERCULOSIS IN HIV INFECTION: 
RADIOGRAPHIC APPEARANCE IS RELATED TO CD4+ T-
L YMPHOCYTE COUNT 
4b SURVIVAL OF HUMAN IMMUNODEFICIENCY VIRUS-
INFECTED PERSONS WITH PULMONARY TUBERCULOSIS 
4c STAGING OF HIV POSITIVE PATIENTS WITH PULMONARY 
TUBERCULOSIS 
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4a PULMONARY TUBERCULOSIS IN HIV INFECTION: RADIOGRAPHIC 
APPEARANCE IS RELATED TO CD4+ T-LYMPHOCYTE COUNT 
(Tubercle Lung Dis 1995; 76:518-521) 
SUMMARY 
Setting: An adult HIV outpatient clinic in Cape Town, South Africa. 
Objective: To investigate the relationship between the radiographic appearance of 
pulmonary tuberculosis (PTB) in HIV infected patients and CD4+ T-lymphocyte 
count. 
Design: Pre-treatment radiographs of 150 patients with newly diagnosed PTB were 
reviewed. CD4+ T-lymphocyte count was used as a marker of HIV disease 
progression. 
Results: Upper zone infiltrate typical of PTB reactivation was present in 18 
patients. This pattern was associated with early HIV infection (mean CD4+ T-cell 
count 389) and had 78% positive predictive value for identifying patients with >200 
CD4+ T-lymphocyteslµL. Pleural effusion was present in 32 patients and occurred 
over a wide intermediate range of CD4+ T-cell counts (mean 185). Lower or mid-
zone infiltrates, adenopathy, interstitial pattern or normal radiograph occurred in 
136 patients and were associated with advanced HIV disease (mean CD4+ T-cell 
count 105). These patterns had 84%, 89%, 89% and 100% positive predictive 
value, respectively, for identifying patients with <200 CD4+ T-cells/µL. 
Conclusion: Pulmonary tuberculosis in African HIV positive patients presents with a 
spectrum of radiographic abnormalities, and specific patterns are predictive of 
44 
stage of HIV disease progression. In patients dually infected with HIV and PTB, 
chest radiographs are a useful adjunct to clinical staging. 
INTRODUCTION 
The interaction between the human immunodeficiency virus (HIV) epidemic and 
pulmonary tuberculosis (PTB) has been recognised in both the developed and 
developing world. In Sub-Saharan Africa, HIV seroprevalence of up to 67% has 




. The World Health 
Organisation (WHO) included PTB as one of the HIV clinical stage 3 criteria 
3 and 
more recently it has been proposed that PTB should be an acquired 
immunodeficiency syndrome (AIDS) defining diagnosis 
4
. In African HIV infected 
patients, however, PTB was found to be a poor marker of stage of disease. In 
areas of high PTB prevalence, individuals may be HIV seropositive and develop 
PTB without significant immunosuppression 
5
. 
Patients dually infected with HIV and PTB frequently present with chest 
radiographic abnormalities that differ from those of PTB in HIV-negative individuals 
s.rn_ This study, conducted in an area with a high PTB prevalence of 1.134/100.000 
11 and an estimated 2.5% HIV seroprevalence 12, investigated the relationship 
between various radiographic patterns and CD4+ T-lymphocyte counts. 
METHODS 
Medical records of adults attending Somerset Hospital HIV outpatient clinic in 
Cape Town, South Africa, from 1989-1994 were examined. Pre-treatment chest 
radiographs of 150 patients (103 M, 47 F, mean age 33, range 17-75) in whom 
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PTB was diagnosed were reviewed. These radiographs and those of 100 
consecutive HIV clinic attendees without respiratory symptoms were reported on by 
a radiologist and categorised in a blinded fashion by 2 physicians independently. In 
case of disparity, the radiologist reviewed the films and was the final arbiter. 
Radiographs with infiltrates localised predominantly in the upper lobes or apical 
segment of the lower lobes with or without cavitation were categorised as typical of 
reactivation (post-primary) PTB. In addition, radiographs were screened for the 
presence of pleural effusions, mediastinal and hilar adenopathy, lobar or 
segmental parenchymal infiltrates, and reticule-nodular or miliary pattern. Fibro-
cystic changes and pleural scarring were considered evidence of previous PTB. 
Patients without typical reactivation pattern could be included into more than one 
category. 
A PTB diagnosis was confirmed on sputum in 104 patients ( smear only n=40, 
smear and culture n=42, sputum culture with negative smear n=22). Pleural fluid 
adenosine deaminase (ADA) and pleural culture/histology (n=B), effusion ADA only 
(n=9), lymph-node histology (n=12), blood culture (n=3) or clinical and radiographic 
response (improvement in body weight, performance score, disappearance of 
pyrexia, cough or respiratory distress; n=14) to 4 drug anti-tuberculous medication 
(lsoniazid, Rifampicin, Ethambutol and Pyrazinamide) suggested active PTB. 
Smear-positive sputum was not routinely cultured. In accordance with WHO 
recommendations 13, HIV seropositivity was confirmed by a combination of four 
positive ELISA assays on two separate blood samples. CD4+ T-lymphocyte counts 
were determined by flow cytometry. 
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Statistical analysis 
Sensitivity, specificity and positive predictive values were calculated with standard 
formulae 14. CD4+ T-lymphocyte counts were expressed as means ± standard 
deviation (SD). CD4+ T-cell counts associated with various radiographic patterns 
were compared by T test. A two-sided level of significance of 0.05 was used to 
reject null hypotheses. 
RESULTS 
The distribution of chest radiographic patterns of PTB in 150 HIV positive patients 
and the mean CD4+ T-lymphocyte count (±SD) associated with each pattern is 
shown in the Figure. Patients with pleural effusions had a significantly lower mean 
CD4+ T-lymphocyte count when compared to those with radiographs typical of 
reactivation PTB (p<0.01 ). Adenopathy, lower or mid-zone parenchymal infiltrates 
and diffuse reticule-nodular or miliary pattern were associated with significantly 
lower mean CD4+ T-cell counts than either pleural effusions (p<0.05) or typical 
reactivation pattern (p<0.01 ). CD4 counts were similar for patients with pleural 
effusions with or without concomitant pulmonary infiltrates. 
Radiographs with typical upper zone infiltrates with or without cavitation had 96% 
specificity and 78% positive predictive value for identifying subjects with >200 
CD4+ T-lymphocytes/µL. Cavitation occurred exclusively within upper zone 
infiltrates. Three patients had a normal chest radiograph, were sputum smear 
positive and had CD4+ T-lymphocyte counts <200/µL. The specificity and positive 
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predictive values for the atypical radiographic patterns for identifying patients with 
<200 CD4+ T-lymphocytes/µL are shown in the Table. Apical fibrocystic disease 
and pleural scarring, representing prior PTB, had no predictive value for HIV stage 
of disease (data not shown) and occurred in 12% of both the patient and control 
population. 
Mycobacterial culture of sputum and pleural effusion was performed in 71 patients. 
M. tuberculosis was the pathogen cultured in 94% (64 of 68 patients), three 
cultures lost viability or became contaminated. Atypical mycobacteria (M.kansasii, 
M.xenopi and 2 undefined non-tuberculous mycobacteria) were isolated from 
sputum of four patients who had <200 CD4+ T-cells/µL. These patients were 
excluded from analysis. 
Sputum smear or culture positivity occurred in 73% of PTB patients with reticulo-
nodular or miliary pattern. Of 100 HIV positive PTB negative controls, 75% had a 
normal chest radiograph, 12% showed evidence of previous PTB, 7% had 
parenchymal infiltrates and 6% a reticulo-nodular pattern. Hilar or mediastinal 
adenopathy was not present in these PTB negative patients and was thus not a 
feature of the persistent generalised lymphadenopathy of HIV infection. 
DISCUSSION 
This study documented that PTB occurred at all stages of HIV infection, and that 
there was a spectrum of chest radiographic presentation related to HIV stage of 
disease. 
In Southern Africa, latent M.tuberculosis infection has been reported to be present 
in the majority of adults 1•2•15, and HIV seronegative adults typically develop 
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reactivation PTB with post-primary infiltrates and cavitation 10•15. This pattern in our 
HIV positive patients was associated with early HIV disease as manifested by 
relatively preserved CD4+ T-cell counts. Pleural effusion, although regarded as a 
marker of early clinical HIV disease 16'17, occurred throughout an intermediate 
range of lymphocyte counts and its presence was less helpful for prediction of HIV 
stage of disease. 
In advanced HIV disease, both PTB reactivation and re-infection radiographically 
resemble primary tuberculosis, with features such as adenopathy and interstitial or 
non-cavitating parenchymal infiltrates 6'17'18. These radiographic abnormalities 
occurred in our patient population despite historic or radiographic evidence of prior 
reactivation PTB. In contrast to miliary PTB in HIV negative patients 19, HIV positive 
patients with reticule-nodular and miliary pattern have multi-bacillary PTB 1 
confirmed in our patients by frequent sputum smear and culture positivity. In 
agreement with previous reports, adenopathy was the best predictor of low CD4+ 
T-lymphocyte count 17'20. 
A histopathological spectrum of M.tuberculosis infection in HIV disease analogous 
to that seen in M.leprae infection has been described 1. This study reports a 
radiographic spectrum of pulmonary tuberculosis related to stage of HIV disease. 
In early HIV disease, a preserved cell mediated response results in paucibacillary 
PTB with apical fibrosis and cavitation. In advanced HIV infection, patients present 
with normal chest radiographs, interstitial patterns or adenopathy and advanced 
immunosuppression results in high bacterial load. The latter radiographic 
appearances of PTB could be regarded AIDS defining criteria in our HIV positive 
patients. 
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Although outpatient records were reviewed, patients had often required hospital 
admission or been referred from the community. The sample of patients might 
therefore be a reasonable representation of HIV-associated tuberculosis in our 
area. Tuberculosis in early HIV disease might have been under-represented, as 
specific abnormalities prompting HIV testing are often absent during early HIV 
infection. HIV serology is extremely sensitive 21 , and multiple ELISA essays 
performed on our patients should ensure a high specificity. Consequently, the 
chance of false HIV seropositivity in our patients should be minimal. 
In Sub-Saharan Africa, PTB is the commonest opportunistic infection in HIV 
disease and CD4+ T-lymphocyte counts are frequently unobtainable. In this setting, 
radiographic criteria are a useful adjunct to clinical HIV disease staging. 
Prospective studies however will be required to confirm these findings in other 
population groups. 
We thank Sr E Fielder and Ms E Horak for their assistance in tracing radiographic records and 
Prof GR Keeton for helpful comments during preparation of this paper. 
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A TYPICAL 
n = 18 
B PLEURAL EFFUSION 
n = 32 
C ATYPICAL INFILTRATE 
n = 51 
D RETICULO • NODULAR 
n = 29 
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Figure. CD4+ T-lymphocyte counts associated with PTB radiographic 
patterns in 150 HIV positive patients. CD4+ T-cell numbers are 
shown as mean ±SD. Pattern A is defined by upper zone infiltrate 
with or without cavitation and pattern C by parenchymal infiltrate in 
mid or lower zone. Pattern A is associated with early HIV disease 
and patterns C, D, and E with advanced HIV infection. Patients may 
be included in one or more of categories B-E. 
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TABLE. The specificity and positive predictive value of atypical PTB 
radiographic patterns for identifying HIV positive patients with 
<200 CD4+ T-cells/µL. 
Radiographic pattern Specificity Positive predictive value 
Normal radiograph (n= 3) 100% 100% 
Reticuloanodular (n=36) 88% 89% 
Adenopathy (n=46) 85% 89% 
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4b SURVIVAL OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED 
PERSONS WITH PULMONARY TUBERCULOSIS 
(Int J Tuberc Lung Dis 1997; 1(1):87) 
We have described the radiological features of 150 HIV-1 infected patients 
presenting with pulmonary tuberculosis to a Cape Town HIV clinic between 1989 
and 1994 1. All patients had confirmed tuberculosis and received rifampicin-based 
short course chemotherapy (6 months RHZ for initial cases, 6 months RHZE for 
relapse cases). Treatment was both supervised (5 days per week) and self-
administered (weekly supply of medication). Subsequent follow-up of this cohort 
demonstrated an overall mortality rate of 41/100 person years. However, different 
radiological presentations of pulmonary tuberculosis were associated with highly 
significant (logrank test P < 0.001) differences of Kaplan-Meier proportional 
survival (Figure). The total lymphocyte count was also found to be a major 
predictor of survival. Sixty-one percent of patients presented with lymphopaenia of 
<1250/µL, 39% had a total lymphocyte count >1250/µL. Lymphopaenic patients 
had a significantly higher mortality rate than those with a normal total lymphocyte 
count (65 vs 2/100 person years, x2 test P < 0. 001 ). 
The 2-year mortality rate of patients with HIV-1 infection and pulmonary 
tuberculosis described by Kassim et al. 2 was considerably lower (20.3/100 person 
years) than that reported by Small et al. 3 and ourselves. Each of these studies 
used rifampicin-based chemotherapy, but the different mortality rates could be 
explained on the basis of differences in study population. The CD4 lymphocyte 
count has been found to be a major determinant of mortality 4, but is frequently 
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unavailable in resource-poor countries. In contrast, chest radiographs and total 
lymphocyte counts are widely available and were powerful prognostic markers of 
mortality in our patients with HIV-1 related pulmonary tuberculosis. These variables 
have such strong impact on mortality that they should be reported and controlled 
for in comparative studies of response to tuberculosis chemotherapy in HIV-
infected individuals. 
Figure. 
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0 12 18 
Mo<ltT1 • 
Number of pa tients at ri s k 
Time (months) 0 6 12 18 24 
Typica l 18 1.5 10 6 5 
Effusion 32 19 14 12 10 
Atypical 100 52 27 14 10 
Kaplan-Meier estimated survival of HIV-infected patients with 
pulmonary tuberculosis, stratified by radiographic appearance. 
Typical presentation includes infiltrates limited to the upper lobes 
or apical segments of lower lobes. Effusion denotes pleural 
effusion. Atypical pattern includes lower and mid-zone infiltrates, 
adenopathy and/or interstitial infiltrates. Survival is significantly 
impaired in those patients presenting with pleural effusion or 
atypical patterns (logrank test P < 0.001 ). 
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4C STAGING OF HIV POSITIVE PATIENTS WITH PULMONARY 
TUBERCULOSIS 
Pulmonary tuberculosis in HIV positive patients presents with a radiographic 
spectrum, ranging from contained, cavitatory upper lobe infiltrates in patients with 
preserved cellular immune response and pleural effusions in patients with partial 
preservation of immunity to radiographic patterns of primary tuberculosis in 
patients with advanced HIV infection 1-3. Survival for HIV positive patients 
presenting with PTB varies significantly with the degree of immunosuppression 
suggested by the chest radiograph 4. Currently, all patients with pulmonary TB are 
included in WHO clinical stage 3. The prognostic accuracy of pulmonary 
tuberculosis in the WHO clinical staging system might be improved by 
incorporation of the prognostic information of chest radiographs. 
In this retrospective analysis, we directly compared the survival of 150 HIV positive 
patients with proven pulmonary tuberculosis and radiographic patterns of either 
post-primary PTB (n=18), primary PTB (adenopathy, mid/lower zone or interstitial 
infiltrates, n=100) or tuberculous pleural effusion (n=32) with the survival of 831 
HIV positive outpatients stratified by WHO clinical stage 1-4 (Table). Statgraphics 
version 6.0 was used to calculate Kaplan-Meier proportional survival, and the log-
rank test to establish statistical difference between survival curves. 
Statistical analysis showed survival to be similar for typical (post-primary) 
reactivation pattern and WHO clinical stage 2 (p=0.93), tuberculous pleural 
effusions and clinical stage 3 (excluding PTB, p=0.65), and atypical (primary) 
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radiographic patterns and AIDS (WHO stage 4, p=0.62). By classifying typical 
reactivation PTB as stage 2, pleural effusion as stage 3 and atypical pattern as 
stage 4, the prognosis of pulmonary tuberculosis in HIV positive patients is 
reflected by the WHO clinical stage. 
Typical reactivation PTB in HIV positive patients occurs in the absence of 
significant HIV induced immune suppression. The atypical patterns, in contrast, are 
associated with advanced HIV infection and low CD4 counts 1-3. They frequently 
coexist with or may be preceded by other opportunistic infections and/or AIDS 
defining illnesses. Patients diagnosed with 'atypical' pulmonary tuberculosis 
should, analogous to HIV positive patients with lymphopenia, be considered for 
cotrimoxazole prophylaxis 6. 
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TABLE: Proportional survival (Kaplan-Meier estimates) for HIV positive 
patients with tuberculosis and WHO clinical stage 1-4 
SURVIVAL (months) 6 12 18 24 
TYPICAL PTB 100% 100% 100% 100% 
WHO STAGE Yz 99% 98% 96% 95% 
PLEURAL EFFUSION 88% 82% 68% 63% 
WHOSTAGE3 89% 76% 69% 62% 
ATYPICAL PTB 74% 54% 38% 34% 
WHO STAGE4 74% 51% 37% 30% 
HIV-infected patients with pulmonary tuberculosis (n=150) are stratified by 
radiographic appearance and HIV positive outpatient clinic attenders (n=831) by 
WHO clinical stage. Typical PTB includes infiltrates limited to the upper lobes or 
apical segments of lower lobes. Atypical PTB includes lower and midzone 
infiltrates, adenopathy and/or interstitial infiltrates. WHO stage 4 equals 
acquired immunodeficiency syndrome (AIDS). Survival was similar for patients 
with typical radiographs and WHO stage 1 or 2 (p=0.93), pleural effusion and 
WHO stage 3 (p=0.65), and atypical PTB and WHO stage 4 (p=0.62). 
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TYPE OF AIDS-DEFINING ILLNESS PREDICTS MORTALITY IN PATIENTS 
WITH AIDS 
62 
Acquired immunodeficiency syndrome in Africa: survival according to AIDS 
defining event 
SYNOPSIS 
Survival of patients with AIDS is related to the degree of HIV-induced 
immunodeficiency. Laboratory markers to assess the severity of immune dysfunction 
are rarely available in Africa, and clinical decisions are frequently based on 
surrogate markers such as performance status and type of opportunistic illnesses. 
The prognostic value of these variables remains to be established for Africans. 
Two hundred and eighty patients with AIDS, as defined by the proposed WHO 
clinical staging system, were stratified according to AIDS defining illness and CD4 
count. Data was analyzed using Kaplan-Meier survival and Cox proportional hazard 
analyses. Median survival following the onset of AIDS was 11.5 months. Extra-
pulmonary tuberculosis was the commonest AIDS defining illness. 
Initial AIDS-defining diseases were stratified into early (extra-pulmonary TB and 
herpes simplex virus infection), intermediate (oesophageal candidiasis, 
Pneumocystis carinii pneumonia, Kaposi sarcoma and cryptococcal meningitis) and 
late diseases (HIV wasting syndrome and encephalopathy) according to median 
survival rates (>12, 6-12, <6 months; log-rank p<0.00001). The relative hazards for 
death associated with intermediate and late diseases ( compared to early diseases) 
were 11 .2 (95% Cl: 2.5-50.3) and 25.0 (4.9-127.6) for patients with CD4 counts 
>200/µL, 2.4 (1 .3-4.7) and 11 .3 (4.4-28.8) with CD4 counts 50-200/µL, and 1.3 (0.7-
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2.2) and 2.9 (1 .6-5.0) for patients with CD4 counts <50/µL. A performance status 
score of 4 predicted 50% mortality at one month, irrespective of co-morbidity. 
The type of AIDS-defining disease is an important determinant of survival, 
particularly in patients with relatively preserved CD4 counts. The stratification of 
patients by type of AIDS-defining illness and performance status may be useful for 
the management of patients with advanced HIV infection in resource-limited 
environments. 
INTRODUCTION 
The disease burden caused by human immunodeficiency virus (HIV) infection has 
been overwhelming health care facilities in many African countries 1. It has been 
suggested that African patients with HIV infection have an increased rate of 
progression from asymptomatic HIV infection to the acquired immunodeficiency 
syndrome (AIDS) compared to patients in the developed world, and this difference 
has been related to limited access to medical care 1. A recent longitudinal cohort 
study from Uganda however showed the rate of progression to AIDS in HIV positive 
patients to be comparable to figl:!res previously reporte_d from the Western world 2. 
Survival of South African AIDS patients, provided with adequate medical care, was 
similar to European and American patients with AIDS 3. 
Laboratory markers that reflect the degree of immunocompromise in HIV infection, 
such as CD4+i"-lymphocyte (CD4) count 4 and quantitative HIV viral load 5, are 
frequently unavailable in Africa. In this setting, prognostic information may be 
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obtained from clinical staging as proposed by the World health Organisation (WHO) 
clinical staging system and the total lymphocyte count 2·6·7. 
Acquired immunodeficiency syndrome includes a variety of opportunistic diseases 
that may occur across a spectrum of immune dysfunction 8. The prognosis of 
patients with AIDS varies accordingly and is influenced significantly by the type of 
AIDS defining illness 3•9•10. Prognostic stratification based on AIDS-defining disease 
and performance status can be performed in the outpatient clinic and does not 
require sophisticated laboratory facilities. It is therefore widely applicable in 
resource-poor settings, and potentially useful to guide resource allocation and 
patient management. This study evaluated outcome of the commonest AIDS 
defining events and poor performance status in a cohort of South African HIV 
positive patients. 
METHODS 
All patients with an AIDS diagnosis (as defined by the proposed WHO clinical 
staging system 11 , which is similar to the Centres for Diseases Control 1987 
_ definition ~ofAIDS 12) attending the HIV outpatient clinics of the University of Cape. 
Town medical school (at Somerset and Groote Schuur Hospitals) were selected 
from computer-based medical records. Survival was analyzed from the onset of 
AIDS, according to type of AIDS-defining illness, for diseases that occurred in at 
least 10 patients. Patients were stratified according to CD4 count (<50,51-
200,>200/µL). CD4 counts performed within 3 months preceding the onset of AIDS-
related illness were used for analysis. 
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All patients received co-trimoxazole prophylaxis, and treatment for tuberculosis (TB), 
herpes simplex infection (HSV), oesophageal candidiasis, Pneumocystis carinii 
pneumonia (PCP) and cryptococcal meningitis was available (Rifampicin based 
short course chemotherapy, valacyclovir, fluconazole, co-trimoxazole and 
amphotericin B / fluconazole respectively). Anti-retroviral therapy was not routinely 
available for patients with AIDS, and patients (n=83) who had received such therapy 
were excluded from analysis. Treatment regimens for opportunistic infections 
remained unchanged throughout the study period. 
Survival was expressed as the Kaplan-Meier estimate of cumulative probability of 
survival and was calculated in months from the index visit (first visit at which the 
condition occurred) to the date of death or last visit (censored). Kaplan-Meier 
survival curves were created using the software package Statistica version 5, and 
evaluated for statistical difference by log-rank test. Relative hazards of death were 
calculated using the univariate Cox proportional hazar~ model of SAS statistical 
program (version 6, SAS institute, Cary NC, USA). 
RESULTS 
By April 1997, 280 patients had developed AIDS, 160 of whom had died . Both 
homosexual (n=109) and heterosexual (n=171) transmission pattern, and male 
(n=199) and female (n=81) sex were represented; intravenous drug abuse and 
haemophilia did not occur as risk factors for HIV infection in our patients. 
The overall median survival from the onset of AIDS was 11.5 months. Initial AIDS-
defining illnesses were stratified into early, intermediate and late events, according 
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to median survival rates (Table 1 ). No statistical difference was present between the 
survival curves of individual diseases within each stratum (p=0.90, 0.43, and 0.98 
respectively). Kaplan-Meier survival for each of the three strata of opportunistic 
diseases is depicted in the figure. AIDS-defining illnesses were associated with a 
poorer outcome when they occurred after the onset of AIDS rather than as initial 
illness, but these differences only reached statistical significance for extra-
pulmonary tuberculosis (data not shown). Performance status score 4 (in bed >50% 
of normal day time during the last month) predicted 50% one-month mortality, 
irrespective of co-morbidity . 
Survival of AIDS patients was dependent on both CD4 count (p<0.00001) and AIDS-
defining illness. The relative hazards of death associated with intermediate and late 
diseases relative to early diseases for the defined strata of CD4 counts are shown in 
Table 2. The influence of AIDS-defining illness on mortality was most striking in 
patients with preserved CD4 counts. 
DISCUSSION 
This study, performed in a resource limited envlromnent, showed that the type of 
AIDS-defining disease was a major predictor of outcome, and that the prognostic 
information provided by the opportunistic disease was additive to the CD4 count. 
Stratification of patients according to AIDS-defining disease and performance status 
is easily performed, and therefore widely applicable in resource-poor settings. The 
prognostic information provided by these clinical parameters can be used for 
counselling and management of HIV infected patients. 
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Extra-pulmonary tuberculosis and HSV infection (lasting more than one month) as 
initial AIDS diagnoses were associated with the most favourable outcome and 
survival was comparable to reported figures from the developed world 9'10. Extra-
pulmonary tuberculosis was the initial AIDS diagnosis in one third of our patients, 
and associated with a relatively preserved CD4 count. Its frequent occurrence may 
explain the more favourable overall prognosis of patients with AIDS in Cape Town 
compared to Uganda 2'3. 
Survival in our patients following cryptococcal meningitis was similar to patients with 
cryptococcosis in a large European study (7 vs 9 months) 10, and Kaposi sarcoma 
(KS) predicted similar outcome as in an American cohort (12 vs 12.3 months) 13. The 
comparability of African and Western AIDS survival figures support the notion that 
access to care is an important determinant of survival of African AIDS patients 1. 
Reports from sub-Saharan Africa suggest that wasting syndrome is common 1·2, and 
post-mortem studies have revealed that tuberculosis is highly prevalent in cachectic 
African AIDS patients 14. HIV positive patients who presented to our clinics with a 
wasting illness were thoroughly investigated for tuberculosis by means of sputum 
smears and culture, histology of lymph node, liver or bone marrow, and blood 
culture. The resulting high frequency with which tuberculosis was diagnosed, and 
the relatively low prevalence of diarrhoeal illnesses in South African HIV positive 
patients 15 may offer an explanation for the small number of patients with 
unexplained HIV-wasting syndrome in this study. 
The type of AIDS-defining disease 9'10, prior HIV or AIDS related morbidity 16, total 
lymphocyte count 5 and performance status 17 all provide useful prognostic 
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information in patients with advanced HIV infection. Prognostic stratification of HIV 
infected patients has particular relevance in resource-poor countries, to avoid 
irrational spending of scarce health care resources. Expensive investigations or 
therapy could be reserved for patients with favourable prognostic criteria. Survival 
figures of patients with performance status 4 or diseases such as HIV wasting 
syndrome or encephalopathy on the other hand support the institution of home-
based terminal care for these patients. 
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TABLE 1 
Median CD4 counts and survival (Kaplan-Meier estimates) for the commonest 
initial AIDS-defining illnesses 
AIDS-defining illness median CD4 median survival (n) 
count (cells/µL) (months) 
early 111 >24 (116) 
extra-pulmonary tuberculosis 111 >24 (97) 
herpes simplex virus 114 >24 (19) 
intermediate 48 9 (105) 
kaposi sarcoma 118 12 (24) 
oesophageal candidiasis 76 9 (32) 
pneumocystis carinii pneumonia 39 7 (38) 
cryptococcal meningitis 32 7 (11) 
late 64 2 (40) 
encephalopathy 121 3 (20) 
wasting 45 1 (20) 
Legend 
Initial AIDS-defining illnesses were stratified into early, intermediate and late 
events according to median survival rates (>12,6-12,<6 months). n reflects the 
number of patients in each stratum. 
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TABLE 2: Relative hazards for death associated with class of AIDS-defining 
illness, for defined strata of CD4 count (95% confidence intervals between 
brackets; values >1 imply (statistically significant) increases in risks of death for 
a particular AIDS defining illnesses relative to early AIDS defining diseases 










class of AIDS-defining illness 
intermediate 
11.2 (2.5-50.3) 
2.4 (1.3- 4.7) 
1.3 (0.7- 2.2) 
late 
25.0 (4.9-127.6) 
11 .3 (4.4- 28.8) 
2.9 (1 .6- 5.0) 
Hazards for death are expressed relative to the risk associated with early AIDS-
defining illnesses (extra-pulmonary TB and herpes simplex) in the same CD4 
count stratum. Intermediate illnesses include Kaposi sarcoma, oesophageal 
candidiasis, PCP and cryptococcal meningitis; late diseases encephalopathy 
and wasting. Figures between brackets are the accompanying 95% confidence 
intervals. 
(AIDS-defining illness occurring as initial event or following the onset of AIDS 
are included) 
The authors wish to gratefully acknowledge Ms M Visser for assisting with the statistical analysis 
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Figure 
Proportional survival (Kaplan-Meier estimates) for patients with AIDS , 
stratified by AIDS-defining illness 
o Complete + Censored 
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Survival for the eight commonest AIDS-defining illnesses could be stratified into one of three patterns; early diseases include extra-pulmonary TB and HSV, 
intermediate diseases KS, oesophageal candidiasis, PCP and cryptococcal 
meningitis, late diseases encephalopathy and wasting. Survival was significantly 
different for early, intermediate and late events (p<0.00001 ). 
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Africa is disproportionally affected by both the human immunodeficiency virus 
(HIV) and tuberculosis (TB) epidemics. Health services in sub-Saharan African 
countries are overwhelmed by the huge number of patients suffering from HIV 
infection and acquired immunodeficiency syndrome, and many of these patients 
will develop active TB. 
To facilitate counselling and rational distribution of scarce health care resources, 
inexpensive and readily available markers of HIV disease progression are 
required. This thesis explored the prognostic value of World Health Organisation 
clinical stage, total lymphocyte count, performance status and type of 
opportunistic infection in patients with HIV infection, and of chest radiographs in 
patients co-infected with tuberculosis. These parameters can be easily assessed 
during an outpatient clinic visit and do not require sophisticated equipment. 
Early HIV infection (WHO clinical stage 1-2) carries a favourable prognosis, with 
annual rates of progression to AIDS below 15%. During early HIV infection 
therefore, patient management should be guided by clinical parameters. Total 
lymphocyte counts below 1250/µI predict a faster progression to AIDS, and 
patients with low lymphocyte counts are at increased risk of preventable 
opportunistic infections, including PCP and toxoplasmosis. Patients with total 
lymphocyte counts below 1250/µI should thus be considered for co-trimoxazole 
prophylaxis, as this intervention may improve outcome. 
Tuberculosis is the commonest opportunistic infection in African HIV infected 
patients. As TB is eminently treatable and a major cause of HIV related morbidity 
76 
morbidity and mortality, its presence should be considered in all patients 
presenting with a respiratory, wasting or diarrhoeal illness. Chest radiographs in 
HIV positive patients with TB provide important prognostic information; typical 
reactivation pattern is encountered in patients with early HIV disease and 
predicts a favourable outcome. The atypical radiographic patterns were 
frequently associated with marked CD4+ T-lymphopenia and clinically advanced 
HIV disease. These patients have a poor prognosis, are markedly immune 
suppressed and as such may benefit from co-trimoxazole prophylaxis. The three 
radiographic presentations of PTB (typical , effusion and atypical) predicted 
distinct survival patterns similar to WHO stage 1/2, 3 and 4 respectively. The 
prognostic value of the WHO clinical staging system would be enhanced if 
typical PTB in African HIV infected patients were to be classified as WHO stage 
2, tuberculous pleural effusion as WHO stage 3, and the atypical presentation of 
PTB as WHO stage 4. 
The prognosis of patients with acquired immunodeficiency syndrome is variable. 
It was shown that AIDS defining diseases could be categorized according to 
outcome as early, intermediate and late events. Whereas the early AIDS 
defining illnesses extra-pulmonary tuberculosis and herpes simplex infection had 
a relatively favourable outcome, poor performance status, HIV wasting syndrome 
and encephalopathy were associated with a very poor prognosis. 
Further validation of the suggested predictors of outcome, and their use in 
clinical practice may indeed facilitate the targeting of scarce health care 
resources at patients with the most favourable prognosis. While patients with 
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early HIV infection should be considered for investigations and treatments 
offered to HIV negative individuals, those who present with the complications of 
advanced AIDS and other markers of poor prognosis are unlikely to benefit from 
such interventions, in which case referral for home-based terminal care may be 
more appropriate. 
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